Related Articles

• Motion sickness: an overview
• Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Article Page

The year 2020 was dominated by the COVID-19 pandemic, bringing with it unprecedented advancements in the fields of healthcare and therapeutic interventions as well as in vaccine and drug development. Nevertheless, several other advancements in various fields of medicine also deserve attention. Herein, the Senior Editors of Drugs in Context provide us with their expert opinion on the events of 2020 and what lies ahead in 2021.

Keywords: antimicrobial resistance, beta-lactams, COVID-19, dexamethasone, insulin icodec, SGLT2 inhibitors, statin therapy, type 2 diabetes.

Citation: Anderson SL, Bassetti M, Mangoni AA. Drugs in Context Editorial: Review of 2020 and what lies ahead in therapeutic interventions. Drugs in Context 2021; 10: 2020-12-10. DOI: 10.7573/dic.2020-12-10

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest relevant to this manuscript. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2021/01/dic.2020-12-10-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2021 Anderson SL, Bassetti M, Mangoni AA. https://doi.org/10.7573/dic.2020-12-10. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2021 Anderson SL, Bassetti M, Mangoni AA. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/drugs-in-context-editorial:-review-of-2020-and-what-lies-ahead-in-therapeutic-interventions

Correspondence: Rosanna Gonzalez-McQuire, BioExcel Publishing Ltd, London, UK. rosanna.gonzalez-mcquire@drugsincontext.com

Provenance: Submitted; externally peer reviewed.

Submitted: 16 December 2020; Accepted: 5 January 2021; Publication date: 22 January 2021.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com